間葉系幹細胞療法の世界市場：市場規模・シェア・動向分析 (種類別・原料別・適応症別・地域別)、セグメント別予測 (2025年～2030年)

間葉系幹細胞療法市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、間葉系幹細胞療法の世界市場規模は2030年までに2億9,660万米ドルに達すると予測され、2025年から2030年にかけて23.5％のCAGRで成長すると予測されています。

間葉系幹細胞（MSC）療法市場は、いくつかの重要な要因によって大きな成長を遂げています。主要な促進要因の1つは、心血管疾患、糖尿病、自己免疫疾患、整形外科疾患などの慢性疾患の有病率の増加です。MSCはユニークな再生特性と免疫調節特性を持っており、これらの慢性疾患の治療に有望な候補となります。様々な細胞タイプに分化し、組織修復を促進するその能力は、MSCベースの治療薬への関心を高めています。慢性疾患の世界の負担が増加し続ける中、MSC療法のような革新的な治療法に対する需要もそれに応じて伸びていくと予想されます。

MSC療法市場を推進するもう一つの重要な要因は、再生医療に対する認識と進歩の高まりです。再生医療は、損傷した細胞、組織、臓器の修復や置換に焦点を当てており、MSCはその多能性により重要な役割を果たしています。この分野では、様々な治療用途にMSCの潜在能力を活用することを目的とした臨床試験や研究活動が急増しています。このような再生ソリューションへの注目の高まりが、MSC療法市場の拡大に寄与しています。

技術の進歩もまた、MSC療法市場を前進させるのに役立っています。幹細胞の分離、培養、操作技術における革新は、MSC療法の効率と効果を高めています。適正製造基準（GMP）に準拠した製品の開発により、一貫した品質と安全性が確保され、より広範な臨床導入が促進されています。このような技術的進歩は、既存の治療を改善するだけでなく、新たな治療応用の道を開き、MSC療法の全体的な需要を増大させています。

さらに、MSC療法市場は、支持的な規制環境と幹細胞研究への資金提供の増加からも恩恵を受けています。政府や研究機関は、臨床試験を促進し、新たな幹細胞治療の承認を迅速化する政策を実施しています。このような恵まれた環境は技術革新を促し、MSC療法の効率的な開発と商業化を可能にしています。さらに、官民双方からの投資が活発化することで、研究イニシアティブや共同研究が促進され、新たなMSC治療の安定したパイプラインが確保されています。

間葉系幹細胞療法市場：分析概要

• 種類別では、同種異系が2024年に73.83％の最大収益シェアで市場全体を支配し、予測期間中に最も速いCAGRで成長する見込みです。治療における同種間葉系幹細胞（MSC）の使用の増加は、健康なドナーから供給され、複数の患者に適用することができるため、市場成長の原動力となっています。これにより、個別化された細胞調達の必要性が減少し、治療がより身近で費用対効果の高いものとなります。
• 原料別では、2024年には脂肪セグメントが37.71%の最大の収益シェアで市場全体を支配し、予測期間中に最も速いCAGRで成長すると予想されます。脂肪由来幹細胞（ADSC）市場は、その高い収量と多能性により拡大しており、様々な慢性疾患や加齢関連疾患に対する効果的な治療を提供しています。細胞加工や製造技術の進歩により、ADSC治療へのアクセスや入手のしやすさが向上し、市場の成長をさらに後押ししています。
• 2024年には、整形外科・筋骨格系疾患分野が適応症別で第2位の市場シェア（25.56%）を占めました。筋骨格系疾患の負担が世界的に増加する中、整形外科領域はMSC療法の中で主要な成長領域であり続けています。
• アジア太平洋は2024年に71.56％の最大市場シェアを占めました。同市場は、政府の支援、医療投資の増加、現地での臨床活動の活発化などに後押しされて急成長を遂げています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 市場の変動要因・傾向・範囲

• 市場の区分と範囲
• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 業界分析ツール
  • SWOT分析;要因別（政治・法律・経済・技術）
  • ポーターのファイブフォース分析
  • COVID-19の影響分析

第4章 間葉系幹細胞療法市場：種類別のビジネス分析

• セグメントダッシュボード
• 世界の間葉系幹細胞療法の変動分析
• 世界の間葉系幹細胞療法の市場規模と動向分析：種類別（2018～2030年）
• 自家移植
• 同種異系

第5章 間葉系幹細胞療法市場：原料別のビジネス分析

• セグメントダッシュボード
• 世界の間葉系幹細胞療法の変動分析
• 世界の間葉系幹細胞療法の市場規模と動向分析：原料別（2018～2030年）
• 骨髄
• 臍帯
• 脂肪
• その他の原料

第6章 間葉系幹細胞療法市場：適応症別のビジネス分析

• セグメントダッシュボード
• 世界の間葉系幹細胞療法の変動分析
• 世界の間葉系幹細胞療法の市場規模と動向分析：適用症別（2018～2030年）
• 整形外科および筋骨格系疾患
• 心血管疾患
• 神経系および中枢神経系疾患
• 血液疾患/免疫疾患
• その他の適応症

第7章 間葉系幹細胞療法市場：地域別の推定・動向分析（種類別・原料別・適応症別）

• 地域別ダッシュボード
• 市場規模の予測と動向分析（2018～2030年）
• 北米
  • 米国
• 欧州
  • 英国
  • ドイツ
• アジア太平洋
  • 日本
  • 韓国
• その他の国

第8章 競合情勢

• 企業/競合の分類
• 戦略マッピング
• 企業ポジション分析（2024年）
• 企業プロファイル/上場企業
  • MEDIPOST, Inc.
  • PHARMICELL Co., Ltd
  • Antrogen
  • CORESTEMCHEMON Inc.
  • NIPRO Corporation
  • STEMPEUTICS RESEARCH PVT LTD
  • JCR Pharmaceuticals Co Ltd
  • Mesoblast, Inc.
  • Cell Tech Pharmed
  • HOLOSTEM Srl
  • Takeda Pharmaceutical Company Limited

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
• Table 4 Global mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
• Table 5 Global mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 6 Global mesenchymal stem cell therapy market, by region, 2018 - 2030 (USD Million)
• Table 7 North America mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
• Table 8 North America mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
• Table 9 North America mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
• Table 10 North America mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 11 U.S. mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
• Table 12 U.S. mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
• Table 13 U.S. mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 14 Europe mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
• Table 15 Europe mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
• Table 16 Europe mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
• Table 17 Europe mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 18 UK mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
• Table 19 UK mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
• Table 20 UK mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 21 Germany mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
• Table 22 Germany mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
• Table 23 Germany mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 24 Asia Pacific mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
• Table 25 Asia Pacific mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
• Table 26 Asia Pacific mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
• Table 27 Asia Pacific mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 28 Japan mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
• Table 29 Japan mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
• Table 30 Japan mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 31 South Korea mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
• Table 32 South Korea mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
• Table 33 South Korea mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 34 Rest of World mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
• Table 35 Rest of World mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
• Table 36 Rest of World mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
• Table 37 Rest of World mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 38 Participant's overview
• Table 39 Financial performance
• Table 40 Key companies undergoing expansions
• Table 41 Key companies undergoing acquisitions
• Table 42 Key companies undergoing collaborations
• Table 43 Key companies launching new products
• Table 44 Key companies undertaking other strategies

List of Figures

• Fig. 1 Mesenchymal stem cell therapy market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Segment snapshot
• Fig. 11 Competitive landscape snapshot
• Fig. 12 Parent market outlook
• Fig. 13 Related/ancillary market outlook
• Fig. 14 Genomics - Industry value chain analysis
• Fig. 15 Mesenchymal stem cell therapy market driver analysis
• Fig. 16 Mesenchymal stem cell therapy market restraint analysis
• Fig. 17 Mesenchymal stem cell therapy market: Porter's analysis
• Fig. 18 Mesenchymal stem cell therapy market: Type outlook and key takeaways
• Fig. 19 Mesenchymal stem cell therapy market: Type market share analysis, 2023 - 2030
• Fig. 20 Global mesenchymal stem cell therapy by autologous market, 2018 - 2030 (USD Million)
• Fig. 21 Global mesenchymal stem cell therapy by allogenic market, 2018 - 2030 (USD Million)
• Fig. 22 Mesenchymal stem cell therapy market: Source outlook and key takeaways
• Fig. 23 Mesenchymal stem cell therapy market: Source market share analysis, 2023 - 2030
• Fig. 24 Global mesenchymal stem cell therapy by umbilical cord market, 2018 - 2030 (USD Million)
• Fig. 25 Global mesenchymal stem cell therapy by adipose market, 2018 - 2030 (USD Million)
• Fig. 26 Global mesenchymal stem cell therapy by other sources market, 2018 - 2030 (USD Million)
• Fig. 27 Mesenchymal stem cell therapy market: Disease indication outlook and key takeaways
• Fig. 28 Mesenchymal stem cell therapy market: Disease indication market share analysis, 2023 - 2030
• Fig. 29 Global mesenchymal stem cell therapy by orthopedic and musculoskeletal disorders market, 2018 - 2030 (USD Million)
• Fig. 30 Global mesenchymal stem cell therapy by cardiovascular diseases market, 2018 - 2030 (USD Million)
• Fig. 31 Global mesenchymal stem cell therapy by neurological and CNS disorders market, 2018 - 2030 (USD Million)
• Fig. 32 Global mesenchymal stem cell therapy by hematological / immune disorders market, 2018 - 2030 (USD Million)
• Fig. 33 Global mesenchymal stem cell therapy by other indications market, 2018 - 2030 (USD Million)
• Fig. 34 Regional marketplace: Key takeaways
• Fig. 35 North America mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 U.S. key country dynamics
• Fig. 37 U.S. mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Europe mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 UK key country dynamics
• Fig. 40 UK mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 41 Germany key country dynamics
• Fig. 42 Germany mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 Asia-Pacific mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 44 Japan key country dynamics
• Fig. 45 Japan mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 46 South Korea key country dynamics
• Fig. 47 South Korea mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 48 Rest of World mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 49 Key company categorization
• Fig. 50 Company market positioning
• Fig. 51 Market participant categorization
• Fig. 52 Strategy framework

Mesenchymal Stem Cell Therapy Market Growth & Trends:

The global mesenchymal stem cell therapy market size is anticipated to reach USD 296.6 million by 2030 and is projected to grow at a CAGR of 23.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The mesenchymal stem cell (MSC) therapy market is experiencing significant growth, driven by several key factors. One major driver is the increasing prevalence of chronic diseases such as cardiovascular conditions, diabetes, autoimmune disorders, and orthopedic ailments. MSCs possess unique regenerative and immunomodulatory properties, making them promising candidates for treating these chronic conditions. Their ability to differentiate into various cell types and promote tissue repair has spurred interest in MSC-based therapeutics. As the global burden of chronic illnesses continues to rise, the demand for innovative treatments like MSC therapy is expected to grow correspondingly.

Another significant factor propelling the MSC therapy market is the growing awareness and advancement in regenerative medicine. Regenerative medicine focuses on repairing or replacing damaged cells, tissues, or organs, and MSCs play a crucial role due to their multipotent nature. The field has witnessed a surge in clinical trials and research activities, aiming to harness the potential of MSCs in various therapeutic applications. This heightened focus on regenerative solutions is contributing to the expansion of the MSC therapy market.

Technological advancements have also been instrumental in driving the MSC therapy market forward. Innovations in stem cell isolation, culture, and manipulation techniques have enhanced the efficiency and effectiveness of MSC therapies. The development of Good Manufacturing Practice (GMP)-compliant products ensures consistent quality and safety, facilitating broader clinical adoption. These technological strides not only improve existing treatments but also open new avenues for therapeutic applications, thereby increasing the overall demand for MSC therapies.

Furthermore, the MSC therapy market benefits from a supportive regulatory environment and increased funding for stem cell research. Governments and institutions are implementing policies that facilitate clinical trials and expedite approvals for new stem cell treatments. This favorable landscape encourages innovation and allows for the efficient development and commercialization of MSC therapies. Additionally, heightened investment from both public and private sectors fosters research initiatives and collaborations, ensuring a steady pipeline of new MSC treatments.

Mesenchymal Stem Cell Therapy Market Report Highlights:

• Based on type, allogenic segment dominated the overall market with the largest revenue share of 73.83% in 2024 and is expected to grow at the fastest CAGR during the forecast period. The increasing use of allogenic mesenchymal stem cells (MSCs) in therapy is driving market growth due to their ability to be sourced from healthy donors and applied to multiple patients. This reduces the need for personalized cell sourcing, making treatments more accessible and cost-effective.
• Based on source, the adipose segment dominated the overall market with the largest revenue share of 37.71% in 2024 and is expected to grow at the fastest CAGR during the forecast period. The market for adipose-derived stem cells (ADSCs) is expanding due to their high yield and multipotency, offering effective treatments for various chronic diseases and age-related conditions. Ongoing advancements in cell processing and manufacturing techniques are enhancing the accessibility and affordability of ADSC therapies, further driving market growth.
• In 2024, orthopedic and musculoskeletal disorders segment held the second-largest market share of 25.56% in the disease indication segment. As the burden of musculoskeletal diseases rises globally, the orthopedic segment continues to be a major growth area within the MSC therapy landscape.
• Asia Pacific accounted for the largest market share of 71.56% in 2024. The market is experiencing rapid growth fueled by government support, rising healthcare investments, and increasing local clinical activity.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Type
  • 1.2.2. Source
  • 1.2.3. Disease Indication
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
    • 3.3.1.1. Broad Therapeutic Potential Across Multiple Diseases
    • 3.3.1.2. Advancements in Cell Culture & Manufacturing Technologies
  • 3.3.2. Market Restraint Analysis
    • 3.3.2.1. Stringent Regulatory Frameworks
• 3.4. Industry Analysis Tools
  • 3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
  • 3.4.2. Porter's Five Forces Analysis
  • 3.4.3. COVID-19 Impact Analysis

Chapter 4. Mesenchymal Stem Cell Therapy Market: Type Business Analysis

• 4.1. Segment Dashboard
• 4.2. Global Mesenchymal Stem Cell Therapy Movement Analysis
• 4.3. Global Mesenchymal Stem Cell Therapy Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Autologous
  • 4.4.1. Global Autologous Market, 2018 - 2030 (USD Million)
• 4.5. Allogenic
  • 4.5.1. Global Allogenic Market, 2018 - 2030 (USD Million)

Chapter 5. Mesenchymal Stem Cell Therapy Market: Source Business Analysis

• 5.1. Segment Dashboard
• 5.2. Global Mesenchymal Stem Cell Therapy Movement Analysis
• 5.3. Global Mesenchymal Stem Cell Therapy Market Size & Trend Analysis, by Source, 2018 to 2030 (USD Million)
• 5.4. Bone Marrow
  • 5.4.1. Global Bone Marrow Market, 2018 - 2030 (USD Million)
• 5.5. Umbilical Cord
  • 5.5.1. Global Umbilical Cord Market, 2018 - 2030 (USD Million)
• 5.6. Adipose
  • 5.6.1. Global Adipose Market, 2018 - 2030 (USD Million)
• 5.7. Others Sources
  • 5.7.1. Global Others Sources Market, 2018 - 2030 (USD Million)

Chapter 6. Mesenchymal Stem Cell Therapy Market: Disease Indication Business Analysis

• 6.1. Segment Dashboard
• 6.2. Global Mesenchymal Stem Cell Therapy Movement Analysis
• 6.3. Global Mesenchymal Stem Cell Therapy Market Size & Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)
• 6.4. Orthopedic and Musculoskeletal Disorders
  • 6.4.1. Global Orthopedic and Musculoskeletal Disorders Market, 2018 - 2030 (USD Million)
• 6.5. Cardiovascular Diseases
  • 6.5.1. Global Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
• 6.6. Neurological and CNS Disorders
  • 6.6.1. Global Neurological and CNS Disorders Market, 2018 - 2030 (USD Million)
• 6.7. Hematological / Immune Disorders
  • 6.7.1. Global Hematological / Immune Disorders Market, 2018 - 2030 (USD Million)
• 6.8. Others Indications
  • 6.8.1. Global Others Indications Market, 2018 - 2030 (USD Million)

Chapter 7. Mesenchymal Stem Cell Therapy Market: Regional Estimates & Trend Analysis by Type, Source, Disease Indication

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. North America Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. South Korea
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. South Korea Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Rest of World
  • 7.6.1. Rest of World Mesenchymal Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. MEDIPOST, Inc.
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. PHARMICELL Co., Ltd
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Antrogen
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. CORESTEMCHEMON Inc.
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. NIPRO Corporation
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. STEMPEUTICS RESEARCH PVT LTD
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. JCR Pharmaceuticals Co Ltd
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Mesoblast, Inc.
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Cell Tech Pharmed
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. HOLOSTEM S.r.l.
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives
  • 8.4.11. Takeda Pharmaceutical Company Limited
    • 8.4.11.1. Overview
    • 8.4.11.2. Financial Performance
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Strategic Initiatives